Healthcare · Biotechnology
Price
$4.76
Market Cap
$172.8M
Employees
54
Beta
0.38
Avg Volume
1,326,922
CEO
Benjamin J. Zeskind
Business Description
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-3.75
Stock Price: $4.76
EPS (Diluted): -1.27
EPS (Diluted): -1.27
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
1.33
Stock Price: $4.76
Total Equity: $218.48M
Shares: 44,011,830
Total Equity: $218.48M
Shares: 44,011,830
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-2.98
Market Cap: $172.80M
Total Debt: $0.00
Cash: $128.65M
EBITDA: -$55.33M
Total Debt: $0.00
Cash: $128.65M
EBITDA: -$55.33M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$164.8M
Market Cap: $172.80M
Total Debt: $0.00
Cash: $128.65M
Total Debt: $0.00
Cash: $128.65M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $4.76
Revenue: $0.00
Shares: 44,011,830
Revenue: $0.00
Shares: 44,011,830
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$698,887
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$59.38M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$56.02M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-25.6%
Net Income: -$56.02M
Total Equity: $218.48M
Total Equity: $218.48M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-66.1%
Operating Income: -$59.38M
Tax Rate: 0.0%
Equity: $218.48M
Total Debt: $0.00
Cash: $128.65M
Tax Rate: 0.0%
Equity: $218.48M
Total Debt: $0.00
Cash: $128.65M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
17.50
Current Assets: $176.25M
Current Liabilities: $10.07M
Current Liabilities: $10.07M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $218.48M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $218.48M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 44,011,830
Shares: 44,011,830
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$4.96
Total Equity: $218.48M
Shares: 44,011,830
Shares: 44,011,830
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.03
Operating CF: -$45.34M
CapEx: -$142,225
Shares: 44,011,830
CapEx: -$142,225
Shares: 44,011,830
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $4.76
Stock Price: $4.76
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$56.02M
Net Income: -$56.02M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IMRX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 11:12pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $2.1M | $316,952 | $0 | $0 | $0 |
| Cost of Revenue | $1.2M | $158,122 | $0 | $0 | $698,887 |
| Gross Profit | $926,888 | $158,830 | $0 | $0 | $-698,887 |
| Operating Expenses | $34.8M | $51.9M | $58.4M | $64.1M | $58.7M |
| Operating Income | -$33.9M | -$51.7M | -$58.4M | -$64.1M | -$59.4M |
| Net Income | -$33.5M | -$50.5M | -$53.5M | -$61.0M | -$56.0M |
| EBITDA | -$33.7M | -$51.5M | -$58.1M | -$63.7M | -$55.3M |
| EPS | $-1.27 | $-1.87 | $-1.88 | $-2.04 | $-1.27 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 11:12pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $74.9M | $72.6M | $59.4M | $36.1M | $128.6M |
| Total Current Assets | $152.3M | $108.7M | $89.1M | $39.6M | $176.2M |
| Total Assets | $166.7M | $122.4M | $102.6M | $52.7M | $232.0M |
| Current Liabilities | $5.6M | $8.1M | $7.8M | $7.5M | $10.1M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $10.7M | $12.5M | $12.0M | $11.3M | $13.5M |
| Total Equity | $156.0M | $109.9M | $90.6M | $41.4M | $218.5M |
| Retained Earnings | -$59.3M | -$109.8M | -$163.3M | -$224.3M | -$280.3M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 11:12pm (9h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$30.9M | -$44.1M | -$49.0M | -$55.0M | -$45.3M |
| Capital Expenditure | $-60,786 | $-742,485 | $-342,746 | $-84,875 | $-142,225 |
| Free Cash Flow | -$30.9M | -$44.8M | -$49.3M | -$55.1M | -$45.5M |
| Acquisitions (net) | $70,348 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $37.8M | -$2.3M | -$13.2M | -$23.3M | $92.5M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:12pm (9h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$16.0M $16.0M – $16.0M
|
$51.8M $51.8M – $51.8M
|
$97.5M $97.5M – $97.5M
|
$198.5M $198.5M – $198.5M
|
| EBITDA |
$3.2M $3.2M – $3.2M
|
$10.3M $10.3M – $10.3M
|
$19.5M $19.5M – $19.5M
|
$39.7M $39.7M – $39.7M
|
| Net Income |
-$58.9M -$68.3M – -$49.5M
|
-$40.1M -$93.7M – $13.6M
|
-$33.9M -$33.9M – -$33.9M
|
$1.0M $1.0M – $1.0M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 11:12pm (9h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -84.8% | -100.0% | — | — |
| Gross Profit Growth | -82.9% | -100.0% | — | — |
| Operating Income Growth | -52.7% | -12.9% | -9.7% | +7.3% |
| Net Income Growth | -50.6% | -5.9% | -14.1% | +8.2% |
| EBITDA Growth | -52.8% | -12.8% | -9.7% | +13.1% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IMRX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IMRX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30